Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Nov;31(6):342–348. doi: 10.1007/BF01741405

Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2

Avi Eisenthal 1
PMCID: PMC11038655  PMID: 2386979

Abstract

Prostaglandins can inhibit the generation of lymphokine-activated killer (LAK) cells by interleukin-2 (IL-2) whereas indomethacin augmented the induction of LAK cells by inhibiting prostaglandin synthesis. In the present study we demonstrate that prostaglandin E2 substantially inhibited the generation of both LAK and antibody-dependent cellular cytotoxicity (ADCC) activity by IL-2. In addition, indomethacin enhanced the induction of LAK activity and ADCC in splenocytes exposed to IL-2 in vitro. The effect of indomethacin was dose-dependent, reaching an optimal effect at 1 µM when 100–1000 units/ml IL-2 were employed. The effect of indomethacin on the generation of ADCC was seen in cells taken from both tumor-bearing mice and normal mice. ADCC induced by IL-2 was augmented by culturing cells from the spleen, liver and lungs, in the presence of indomethacin. ADCC induced in the presence of IL-2 and indomethacin was mediated by cells that were mainly plastic non-adherent cells and expressed the asialo-GM1 glycolipid. The potential of indomethacin in combined therapy with cytokines and specific anti-tumor monoclonal antibodies is discussed.

Keywords: Monoclonal Antibody, Cancer Research, Prostaglandin, Indomethacin, Normal Mouse

References

  • 1.Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol. 1980;124:2682–2682. [PubMed] [Google Scholar]
  • 2.Eisenthal A, Rosenberg SA. Systemic induction of cells mediating antibody dependent cellular cytotoxicity (ADCC) following the administration of interleukin-2. Cancer Res. 1989;49:6953–6953. [PubMed] [Google Scholar]
  • 3.Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 1987;47:2771–2771. [PubMed] [Google Scholar]
  • 4.Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res. 1988;48:7140–7140. [PubMed] [Google Scholar]
  • 5.Eisenthal A, Shiloni E, Rosenberg SA. Characterization of IL-2-induced murine cells which exhibit ADCC activity. Cell Immunol. 1988;115:257–257. doi: 10.1016/0008-8749(88)90180-3. [DOI] [PubMed] [Google Scholar]
  • 6.Fulton AM. Inhibition of experimental metastasis with indomethacin: Role of macrophages and natural killer cells. Prostaglandins. 1988;35:413–413. doi: 10.1016/0090-6980(88)90132-3. [DOI] [PubMed] [Google Scholar]
  • 7.Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med. 1977;146:1719–1719. doi: 10.1084/jem.146.6.1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Henney CS, Bourne HR, Lichtenstein LM. The role of 3' 5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol. 1971;108:1526–1526. [PubMed] [Google Scholar]
  • 9.Honda M, Steinberg AD. Effects of prostaglandin E2 on responses of T-cell subsets to mitogen and autologous non-T-cell stimulation. Clin Immunol Immunopathol. 1984;33:111–111. doi: 10.1016/0090-1229(84)90297-6. [DOI] [PubMed] [Google Scholar]
  • 10.Ibayashi Y, Hoon DS, Golub SH. The regulatory effect of adherent cells on lymphokine activated killer cells. Cell Immunol. 1987;110:365–365. doi: 10.1016/0008-8749(87)90129-8. [DOI] [PubMed] [Google Scholar]
  • 11.Kanar MC, Thiele DL, Ostensen M, Lipsky PE. Regulation of human natural killer (NK) cell function: induction of killing of an NK-resistant renal carcinoma cell line. J Clin Immunol. 1988;8:69–69. doi: 10.1007/BF00915159. [DOI] [PubMed] [Google Scholar]
  • 12.Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masunio T, Kishimoto S. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res. 1988;48:1173–1173. [PubMed] [Google Scholar]
  • 13.Lala PK, Parhar RS. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin-2: characteristics of killer cells generated in situ. Cancer Res. 1988;48:1072–1072. [PubMed] [Google Scholar]
  • 14.Lala PK, Kennedy TG, Parhar RS. Suppression of lymphocyte alloreactivity by early gestational human decidua II. Characterization of the suppressor mechanisms. Cell Immunol. 1988;116:411–411. doi: 10.1016/0008-8749(88)90241-9. [DOI] [PubMed] [Google Scholar]
  • 15.Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature. 1980;288:597–597. doi: 10.1038/288597a0. [DOI] [PubMed] [Google Scholar]
  • 16.Murray JL, Down J, Hersh EM. In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. J Biol Response Mod. 1986;5:12–12. [PubMed] [Google Scholar]
  • 17.Ogawa M, Mori T, Mori Y, Ueda S, Yoshida H, Kato I, Iesato K, Wakashin Y, Wakashin M, Okuda K. Inhibitory effects of prostaglandin E1 on T-cell mediated cytotoxicity against isolated mouse liver cells. Gastroenterology. 1988;94:1024–1024. doi: 10.1016/0016-5085(88)90562-8. [DOI] [PubMed] [Google Scholar]
  • 18.Okumura Y, Ishibashi H, Shirahama M, Kurokawa S, Kudo J, Okubo H, Niho Y. Kupffer cells modulate natural killer cell activity in vitro by producing prostaglandins. Cell Immunol. 1987;107:89–89. doi: 10.1016/0008-8749(87)90268-1. [DOI] [PubMed] [Google Scholar]
  • 19.Parhar RS, Lala PK. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin-2. J Exp Med. 1987;165:14–14. doi: 10.1084/jem.165.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pedersen BK, Oxholm P, Klarlund K. Characterization of the in vivo and in vitro effects of indomethacin on human natural killer cell activity. Allergy. 1986;41:532–532. doi: 10.1111/j.1398-9995.1986.tb00339.x. [DOI] [PubMed] [Google Scholar]
  • 21.Pedersen BK, Kharazmi A, Svenson M. Down-regulation of natural killer cell activity by autologous polymorphonuclear leucocytes. Role of indomethacin. Allergy. 1988;43:17–17. doi: 10.1111/j.1398-9995.1988.tb02039.x. [DOI] [PubMed] [Google Scholar]
  • 22.Pelus LM, Ottmann OG, Nocka KH. Synergistic inhibition of human bone marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-α, and γ, and an effect mediated by tumor necrosis factor. J Immunol. 1988;140:479–479. [PubMed] [Google Scholar]
  • 23.Remick DG, Larrick JW, Nguyen DT, Kunkel SL. Stimulation of prostaglandin E2 and thromboxane B2 production by human monocytes in response to interleukin-2. Biochem Biophys Res Commun. 1987;147:86–86. doi: 10.1016/s0006-291x(87)80090-6. [DOI] [PubMed] [Google Scholar]
  • 24.Remick DG, Kunkel SL, Higashi GI, Hiserodt JC. Suppression of natural killer cytolytic activity in mice undergoing pulmonary granulomatous inflammation. J Immunol. 1988;140:2225–2225. [PubMed] [Google Scholar]
  • 25.Rita M, Young I, Young ME, Kim K. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2 . Cancer Res. 1988;48:6826–6826. [PubMed] [Google Scholar]
  • 26.Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin 2 produced inEscherichia coli . Science. 1984;223:1412–1412. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  • 27.Sachs DH, Cone JL. A murine B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. J Exp Med. 1973;138:1289–1289. doi: 10.1084/jem.138.6.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol. 1987;138:1992–1992. [PubMed] [Google Scholar]
  • 29.Shultz RM, Pavlidis NA, Slylos WA, Chirigos MA. Regulation of macrophage tumoricidal functions: a role of prostaglandins of E-series. Science. 1978;202:320–320. doi: 10.1126/science.694537. [DOI] [PubMed] [Google Scholar]
  • 30.Sileghem M, Darji A, Remels L, Hamers R, Baetselier PD. Different mechanism account for the suppression of interleukin 2 production and the suppression of interleukin 2 receptor expression in trypanosoma brucei-infected mice. Eur J Immunol. 1989;19:119–119. doi: 10.1002/eji.1830190119. [DOI] [PubMed] [Google Scholar]
  • 31.Smith KA, Lachman LB, Oppenheim JJ, Favata FM. The functional relationship of the interleukins. J Exp Med. 1980;151:1551–1551. doi: 10.1084/jem.151.6.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R. Systemic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 1987;47:5725–5725. [PubMed] [Google Scholar]
  • 33.Voth R, Chemielarczyk W, Storch E, Kirchner H. Induction of natural killer cell activity in mice by injection of indomethacin. Nat Immun Cell Growth Regul. 1986;5:314–314. [PubMed] [Google Scholar]
  • 34.Webb DR, Nowowiejski I. The role of prostaglandins in the control of primary 19S immune response to SRBC. Cell Immunol. 1975;33:1–1. doi: 10.1016/0008-8749(77)90129-0. [DOI] [PubMed] [Google Scholar]
  • 35.Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J Exp Med. 1987;166:1716–1716. doi: 10.1084/jem.166.6.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Young MR, Newby M. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice. J Natl Cancer Inst. 1986;77:1255–1255. [PubMed] [Google Scholar]
  • 37.Young MR, Endicott RA, Duffie GP, Wepsic HT. Suppressor alveolar macrophages in mice bearing metastatic Lewis lung carcinoma tumors. J Leukocyte Biol. 1987;42:682–682. doi: 10.1002/jlb.42.6.682. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES